Myelodysplastic Syndrome/Acute Myeloid Leukemia Clinical Trials

10 clinical trials for Myelodysplastic Syndrome/Acute Myeloid Leukemia across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant — RECRUITING · PHASE2
• Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia — RECRUITING · PHASE1
• Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes — RECRUITING · PHASE1
• A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS — RECRUITING · PHASE1
• AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies — NOT_YET_RECRUITING · PHASE1
• Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia — SUSPENDED · PHASE1
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — COMPLETED · PHASE2
• Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide — WITHDRAWN · PHASE1

Refine this search